Episode Details

Back to Episodes
Pharmaceutical Executive Daily: Eli Lilly Reports Positive Results from Two Phase III Trials

Pharmaceutical Executive Daily: Eli Lilly Reports Positive Results from Two Phase III Trials

Published 3 months, 3 weeks ago
Description
In today's Pharmaceutical Executive Daily, Eli Lilly's Retatrutide delivers up to 22.6% weight loss in two new Phase III trials, a clinical trial expert discusses why the U.S. is losing trial volume to Australia and China, and a pharmacy benefits executive weighs in on why short-term cost thinking is complicating GLP-1 coverage decisions.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us